비교리스트

 카트 문의
시장보고서
상품코드
1586371

세계의 폐렴구균 백신 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 백신 유형별, 제품 유형별, 최종 사용자별, 지역별, 부문별 예측(2024-2032년)

Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024 - 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 폐렴구균 백신 시장 규모는 2032년까지 144억 3,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

폐렴구균 백신 시장은 폐렴구균 감염에 대한 인식이 높아지고 정부가 후원하는 예방접종 프로그램이 확대되면서 크게 성장하고 있습니다. 공중보건 캠페인이 폐렴과 수막염을 포함한 폐렴구균성 질환의 위험성을 강조함에 따라 개인과 의료 서비스 제공업체들은 백신 접종에 대한 관심이 높아지고 있습니다. 또한, 각국 정부는 지역사회의 건강을 증진하고 폐렴구균 감염과 관련된 의료 비용을 줄이기 위해 강력한 예방접종 이니셔티브를 시행하고 있습니다. 이러한 프로그램에는 종종 보조금과 교육 자원이 포함되어 있어, 백신 접종에 대한 접근성이 낮은 사람들에게 백신을 더 쉽게 접종할 수 있도록 돕고 있습니다. 예방접종에 대한 인식이 높아지고 예방접종에 대한 노력이 강화됨에 따라 폐렴구균 백신에 대한 수요가 크게 증가하여 폐렴구균 백신 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.

폐렴구균 백신 시장은 백신 접종을 광범위하게 장려하는 정부의 이니셔티브와 보건 정책에 의해 주도되고 있습니다. 이러한 프로그램은 폐렴 및 수막염과 같은 폐렴구균성 질환의 발생률을 감소시킴으로써 공중 보건을 개선하는 것을 목표로 합니다. 정부가 자금 지원과 인식 개선 캠페인을 포함한 종합적인 예방접종 전략을 시행함에 따라 백신에 대한 접근성이 개선되고 백신 접종률이 향상될 수 있습니다.

보다 효과적인 폐렴구균 결합 백신(PCV)을 개발하기 위한 생명공학 기업과 시장 기업의 파트너십 개발이 증가하면서 예측 기간 동안 폐렴구균 백신 시장의 성장에 박차를 가하고 있습니다. 예를 들어, 2023년 6월 SK바이오사이언스는 사노피와 공동으로 21가 PCV인 GBP410을 개발했으며, 영아 및 유아를 대상으로 한 임상 2상 시험에서 좋은 결과를 보였습니다. 마찬가지로 2024년 3월 화이자의 20가 PCV인 프리베나 20은 유럽위원회로부터 유럽 전역 및 전 세계 영유아, 소아, 청소년을 대상으로 한 예방접종 승인을 획득했습니다. 이러한 전략적 제휴는 연구 역량 강화, 시장 개발 가속화, 백신 접근성 확대를 통해 향후 몇 년동안 시장 성장을 가속할 것으로 예상됩니다.

폐렴구균 백신 시장 보고서 하이라이트

폐렴구균 다당류 백신(PPV) 부문은 2023년 가장 큰 시장 점유율을 차지했는데, 이는 주로 전 세계적으로 수용되고 쉽게 구할 수 있기 때문입니다.

폐렴구균 결합 백신(PCV) 부문은 PCV가 폐렴구균을 더 광범위하게 커버하기 때문에 조사 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

Prebner 13은 다양한 연령층에 적용 가능하고 보다 효율적인 치료가 가능하여 2023년 가장 큰 시장 점유율을 차지했습니다.

폐렴구균 백신 개발에 대한 투자가 증가함에 따라 아시아태평양이 조사 기간 동안 가장 빠른 성장을 기록할 것으로 예상됩니다.

세계 기업으로는 GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd, Sanofi 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 폐렴구균 백신 시장 인사이트

  • 시장 현황
  • 폐렴구균 백신 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • PESTEL 분석
  • 폐렴구균 백신 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 폐렴구균 백신 시장 : 백신 타입별

  • 주요 조사 결과
  • 서론
  • 폐렴구균 결합 백신
  • 폐렴구균 다당체 백신

제6장 세계의 폐렴구균 백신 시장 : 제품별

  • 주요 조사 결과
  • 서론
  • Prevnar 13
  • Synflorix
  • Pneumovax23
  • 기타 제품

제7장 세계의 폐렴구균 백신 시장 : 최종사용자별

  • 주요 조사 결과
  • 서론
  • 공공 부문
  • 민간 부문

제8장 세계의 폐렴구균 백신 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 폐렴구균 백신 시장 평가 : 지역, 2019년-2032년
  • 북미
    • 북미 : 백신 유형별, 2019년-2032년
    • 북미 : 제품별, 2019년-2032년
    • 북미 : 최종사용자별, 2019-2032년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 백신 유형별, 2019년-2032년
    • 유럽 : 제품별, 2019년-2032년
    • 유럽 : 최종사용자별, 2019년-2032년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 백신 유형별, 2019년-2032년
    • 아시아태평양 : 제품별, 2019년-2032년
    • 아시아태평양 : 최종사용자별, 2019년-2032년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 백신 유형별, 2019년-2032년
    • 중동 및 아프리카 : 제품별, 2019년-2032년
    • 중동 및 아프리카 : 최종사용자별, 2019년-2032년
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 백신 유형별, 2019년-2032년
    • 라틴아메리카 : 제품별, 2019년-2032년
    • 라틴아메리카 : 최종사용자별, 2019년-2032년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • GSK plc
  • Pfizer Inc.
  • Merck KGaA
  • Serum Institute of India Pvt. Ltd.
  • CSL Ltd.
  • Sanofi S.A
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd
  • Johnson & Johnson
  • AstraZeneca
  • Novavax
LSH 24.11.28

The global pneumococcal vaccine market size is expected to reach USD 14.43 billion by 2032, according to a new study by Polaris Market Research. The report "Pneumococcal Vaccine Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pneumococcal vaccine market is experiencing significant growth driven by increased awareness about pneumococcal infections and the expansion of government-sponsored immunization programs. As public health campaigns highlight the dangers of pneumococcal disease, including pneumonia and meningitis, individuals and healthcare providers are more inclined to seek vaccination. Additionally, governments worldwide are implementing robust immunization initiatives aimed at enhancing community health and reducing healthcare costs associated with pneumococcal diseases. These programs often include subsidies and educational resources, making vaccines more accessible to underserved populations. As awareness continues to rise and vaccination efforts intensify, the demand for pneumococcal vaccines is expected to increase substantially, impacting the pneumococcal vaccine market growth positively.

The pneumococcal vaccine market is driven by government initiatives and health policies that promote widespread vaccination. These programs aim to enhance public health by reducing the incidence of pneumococcal diseases, such as pneumonia and meningitis. As governments implement comprehensive immunization strategies, including funding and awareness campaigns, accessibility to vaccines improves, leading to higher vaccination rates.

Increasing partnerships between biotech firms and market players aimed at developing more effective pneumococcal conjugate vaccines (PCVs) are fueling the pneumococcal vaccine market growth in forecast years. For Instance, in June 2023, SK Bioscience collaborated with Sanofi to create GBP410, a 21-valent PCV that demonstrated positive results in Phase 2 studies involving toddlers and infants. Similarly, in March 2024, Pfizer's PREVENAR 20, a 20-valent PCV, received approval from the European Commission to immunize infants, children, and adolescents across Europe and globally. These strategic alliances enhance research capabilities, expedite development timelines, and expand vaccine access, ultimately driving market growth during projected years.

Pneumococcal Vaccine Market Report Highlights

The pneumococcal polysaccharide vaccine (PPV) segment accounted for the largest market share in 2023 primarily due to global acceptance and easy availability.

The Pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, as PCV covers more range of the streptococcus pneumoniae.

The Prevnar 13 segment accounted for the largest market share in 2023, as it caters to a wider range of age, and is more efficient in treating the disease.

The Asia Pacific is projected to register the fastest growth over the study period, attributable to the increasing investment in pneumococcal vaccine development.

The global players are GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd., and Sanofi.

Polaris Market Research has segmented the pneumococcal vaccine market report based on vaccine type, product type, distribution channel, and region:

By Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Pneumococcal conjugate vaccine (PCV)
  • Pneumococcal polysaccharide vaccine (PPV)

By Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Prevnar 13
  • Synflorix
  • Pneumovax23

By Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Distribution partner companies
  • Non-governmental Organizations
  • Government Authorities

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Vaccine Types
    • 3.2.1. Primary Vaccine Types
    • 3.2.2. Secondary Vaccine Types

4. Global Pneumococcal Vaccine Market Insights

  • 4.1. Pneumococcal Vaccine Market - Market Snapshot
  • 4.2. Pneumococcal Vaccine Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Pneumococcal Disease Across All Age Groups is Driving Market Growth
      • 4.2.1.2. Health Policies Promoting Widespread Vaccination is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Regulatory Hurdles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pneumococcal Vaccine Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pneumococcal Vaccine Market, by Vaccine Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • 5.3. Pneumococcal conjugate vaccine
    • 5.3.1. Global Pneumococcal Vaccine Market, by Pneumococcal conjugate vaccine, by Region, 2019-2032 (USD billion)
  • 5.4. Pneumococcal polysaccharide vaccine
    • 5.4.1. Global Pneumococcal Vaccine Market, by Pneumococcal polysaccharide vaccine, by Region, 2019-2032 (USD billion)

6. Global Pneumococcal Vaccine Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • 6.3. Prevnar 13
    • 6.3.1. Global Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2019-2032 (USD billion)
  • 6.4. Synflorix
    • 6.4.1. Global Pneumococcal Vaccine Market, by Synflorix, by Region, 2019-2032 (USD billion)
  • 6.5. Pneumovax23
    • 6.5.1. Global Pneumococcal Vaccine Market, by Pneumovax23, by Region, 2019-2032 (USD billion)
  • 6.6. Other Product
    • 6.6.1. Global Pneumococcal Vaccine Market, by Other Product, by Region, 2019-2032 (USD billion)

7. Global Pneumococcal Vaccine Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 7.3. Public Sector
    • 7.3.1. Global Pneumococcal Vaccine Market, by Public Sector, by Region, 2019-2032 (USD billion)
  • 7.4. Private Sector
    • 7.4.1. Global Pneumococcal Vaccine Market, by Private Sector, by Region, 2019-2032 (USD billion)

8. Global Pneumococcal Vaccine Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • 8.3. Pneumococcal Vaccine Market - North America
    • 8.3.1. North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.3.2. North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.3.3. North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.4. Pneumococcal Vaccine Market - U.S.
      • 8.3.4.1. U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.4.2. U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.4.3. U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.5. Pneumococcal Vaccine Market - Canada
      • 8.3.5.1. Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.5.2. Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.5.3. Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.4. Pneumococcal Vaccine Market - Europe
    • 8.4.1. Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.4.2. Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.4.3. Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.4. Pneumococcal Vaccine Market - UK
      • 8.4.4.1. UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.4.2. UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.4.3. UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.5. Pneumococcal Vaccine Market - France
      • 8.4.5.1. France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.5.2. France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.5.3. France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.6. Pneumococcal Vaccine Market - Germany
      • 8.4.6.1. Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.6.2. Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.6.3. Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.7. Pneumococcal Vaccine Market - Italy
      • 8.4.7.1. Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.7.2. Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.7.3. Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.8. Pneumococcal Vaccine Market - Spain
      • 8.4.8.1. Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.8.2. Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.8.3. Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.9. Pneumococcal Vaccine Market - Netherlands
      • 8.4.9.1. Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.9.2. Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.9.3. Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.10. Pneumococcal Vaccine Market - Russia
      • 8.4.10.1. Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.10.2. Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.10.3. Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.11. Pneumococcal Vaccine Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.11.2. Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.11.3. Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.5. Pneumococcal Vaccine Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.5.2. Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.5.3. Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.4. Pneumococcal Vaccine Market - China
      • 8.5.4.1. China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.4.2. China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.4.3. China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.5. Pneumococcal Vaccine Market - India
      • 8.5.5.1. India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.5.2. India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.5.3. India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.6. Pneumococcal Vaccine Market - Malaysia
      • 8.5.6.1. Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.6.2. Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.6.3. Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.7. Pneumococcal Vaccine Market - Japan
      • 8.5.7.1. Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.7.2. Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.7.3. Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.8. Pneumococcal Vaccine Market - Indonesia
      • 8.5.8.1. Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.8.2. Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.8.3. Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.9. Pneumococcal Vaccine Market - South Korea
      • 8.5.9.1. South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.9.2. South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.9.3. South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.10. Pneumococcal Vaccine Market - Australia
      • 8.5.10.1. Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.10.2. Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.10.3. Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.11. Pneumococcal Vaccine Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.6. Pneumococcal Vaccine Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.6.2. Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.6.3. Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.4. Pneumococcal Vaccine Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.4.2. Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.4.3. Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.5. Pneumococcal Vaccine Market - UAE
      • 8.6.5.1. UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.5.2. UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.5.3. UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.6. Pneumococcal Vaccine Market - Israel
      • 8.6.6.1. Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.6.2. Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.6.3. Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.7. Pneumococcal Vaccine Market - South Africa
      • 8.6.7.1. South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.7.2. South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.7.3. South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.8. Pneumococcal Vaccine Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.7. Pneumococcal Vaccine Market - Latin America
    • 8.7.1. Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.7.2. Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.7.3. Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.4. Pneumococcal Vaccine Market - Mexico
      • 8.7.4.1. Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.4.2. Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.4.3. Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.5. Pneumococcal Vaccine Market - Brazil
      • 8.7.5.1. Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.5.2. Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.5.3. Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.6. Pneumococcal Vaccine Market - Argentina
      • 8.7.6.1. Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.6.2. Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.6.3. Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.7. Pneumococcal Vaccine Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.7.2. Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.7.3. Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. GSK plc
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Merck KGaA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Serum Institute of India Pvt. Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. CSL Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi S.A
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Walvax Biotechnology Co., Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Beijing Minhai Biotechnology Co., Ltd
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson & Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. AstraZeneca
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Novavax
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제